晚期卵巢癌患者接受新辅助化疗与间歇性减瘤术后脓毒症不良事件的风险因素及其对生存的影响
回顾性分析69例晚期上皮性卵巢癌患者,均接受三周期新辅助化疗(NACT)、间歇性减瘤术(IDS)及辅助化疗。NACT期间贫血(血红蛋白<8 g/dL,p=0.004)是辅助化疗期间脓毒症不良事件的唯一独立危险因素;发生脓毒症不良事件者总生存显著缩短(中位82.3 vs 17.3个月,p=0.007)。
要点
- NACT期间3级贫血(血红蛋白<8 g/dL)是辅助化疗期间脓毒症不良事件的独立危险因素。
- 发生脓毒症不良事件的患者总生存显著缩短(中位82.3 vs 17.3个月,p=0.007)。
- 作者建议对该患者群体调整辅助化疗方案与剂量并加强随访评估。
核心结论
- NACT期间3级贫血可能是辅助化疗期间脓毒症不良事件的早期指标。
- 考虑到对生存的不良影响,作者建议对该患者群体调整辅助化疗方案与剂量并确保仔细的随访评估。
研究设计与样本
- 回顾性研究,纳入2004年至2017年69例晚期上皮性卵巢癌患者,均接受三周期NACT后行IDS及辅助化疗。
主要发现
- 69例患者中,NACT期间发生3级或4级中性粒细胞减少27例(39.1%)、贫血6例(8.8%)、血小板减少2例(2.9%)。
- 13例(18.8%)在辅助化疗期间出现中性粒细胞减少性发热伴脓毒症,2例(2.9%)死于脓毒症休克。
- 合并内科疾病、IDS期间脾切除、NACT期间贫血或血小板减少是脓毒症不良事件的显著危险因素。
- 多因素分析中,NACT期间贫血(血红蛋白<8 g/dL,p=0.004)是辅助化疗期间脓毒症不良事件的唯一显著相关因素。
- 无进展生存无显著差异,但发生脓毒症不良事件者总生存显著缩短(中位82.3 vs 17.3个月,p=0.007)。
关键数值与推荐
- NACT期间贫血定义为血红蛋白<8 g/dL,多因素分析p=0.004。
- 脓毒症不良事件组中位总生存17.3个月 vs 无脓毒症不良事件组82.3个月(p=0.007)。
临床怎么用
- 作者认为NACT期间3级贫血可能是辅助化疗期间脓毒症不良事件的早期指标。
- 作者建议对该患者群体调整辅助化疗方案与剂量,并确保仔细的随访评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to analyze risk factors for septic complications during adjuvant chemotherapy and their impact on survival in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). METHODS: We retrospectively reviewed the medical records of 69 patients with advanced epithelial ovarian cancer from 2004 to 2017. All patients underwent three cycles of NACT followed by IDS and adjuvant chemotherapy. We identified grade 3 or 4 hematologic complications and severe adverse events accompanied by neutropenia, including sepsis or septic shock, that occurred during treatment. Clinicopathologic data including demographic factors, preoperative medical conditions, surgical procedures, and survival times were evaluated. RESULTS: Of 69 patients, 27 (39.1%), 6 (8.8%), and 2 (2.9%) patients experienced grade 3 or 4 neutropenia, anemia, and thrombocytopenia, respectively, during NACT. Thirteen patients (18.8%) had a neutropenic fever with sepsis and 2 patients (2.9%) died of septic shock during adjuvant chemotherapy. Concurrent medical disease, splenectomy during IDS, and anemia or thrombocytopenia during NACT were significant risk factors for septic adverse events. In multivariate analysis, anemia (hemoglobin < 8 g/dL, p = 0.004) during NACT was the only significant factor associated with septic adverse events during adjuvant chemotherapy. Although there was no significant difference in progression-free survival, overall survival was significantly shorter in patients with septic adverse events (median, 82.3 vs. 17.3 months, p = 0.007). CONCLUSIONS: Grade 3 anemia during NACT may be an early indicator for septic adverse events during adjuvant chemotherapy. Considering the adverse impact on survival, scheme and dose of adjuvant chemotherapy should be tailored, and careful follow-up evaluation should be ensured in this patient group.
引用
- Son JH, Lee JH, Jung JA, et al. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery. Gynecol Oncol. 2018. PMID: 30122310. doi:10.1016/j.ygyno.2018.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。